查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553520

肝癌药物市场规模、份额和趋势分析报告：按药物、类型、分销管道、地区和细分市场趋势：2024-2030

Liver Cancer Drug Market Size, Share & Trends Analysis Report By Drug (Targeted Therapy, Immunotherapy, Chemotherapy), By Type, By Distribution Channel, By Region And Segment Forecasts 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

肝癌药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计2030年全球肝癌药物市场规模将达到98.1亿美元，2024年至2030年复合年增长率为17.8%。

肝癌市场的成长很大程度上取决于新药的供应、强大的产品线的存在以及公众意识的提高等因素。肝癌患者数量的增加是由于不健康的生活方式和人口老化的增加所造成的。这有利于肝癌药物市场。针对不能耐受多吉美患者的二线治疗药物的开发预计将对肝癌领域产生重大影响。

肝癌是全球第五大常见癌症，占癌症死亡人数的 9.0%。 2012年，新诊断肝癌人数为782,451人，死于肝癌的人数为745,533人。由于其高度侵袭性和低存活率，原发性肝癌仍然是一个重要的公共卫生问题。肝细胞癌占原发性肝癌的大部分（75-90%）。肝癌的许多显着原因，包括肝炎感染和肝硬化，都是可以改变的，生活方式改变和肝炎疫苗接种等预防策略为降低肝癌的发病率和死亡率提供了广阔的前景。

肝癌药物市场报告亮点

  • 由于标靶治疗涉及癌细胞生长和扩散的特定分子或途径的高精度，标靶治疗治疗领域在 2023 年占据最大的市场收益占有率，为 53.0%。
  • 肝细胞癌（HCC）在肝癌药物市场中占据主导地位，2023 年收益占有率为 36.6%。肝细胞癌是最常见的原发性肝癌类型。
  • 医院药房主导肝癌药物市场，2023年收益占有率为45.5%。
  • 2023年北美肝癌药物市场占销售量42.​​7%。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章肝癌药物市场的变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 肝癌药物市场分析工具
    • 波特的分析
    • PESTEL分析

第四章肝癌药物市场：按药物分类的估计和趋势分析

  • 细分仪表板
  • 肝癌药物市场：2018-2030年药物波动分析
  • 标靶治疗
  • 免疫疗法
  • 化疗

第五章肝癌药物市场：依类型估计及趋势分析

  • 细分仪表板
  • 肝癌药物市场：2018年及2030年类型变化分析
  • 肝细胞癌
  • 胆管癌
  • 肝母细胞瘤

第六章肝癌药物市场：依通路估算与趋势分析

  • 细分仪表板
  • 肝癌药物市场：2018年及2030年通路变化分析
  • 医院药房
  • 零售药房
  • 网路药房

第七章肝癌药物市场：区域估计与趋势分析

  • 2023 年及 2030 年肝癌药物市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国。
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Merck KGaA
    • Exelixis, Inc.
    • Eisai Co., Ltd.
    • Bristol-Myers Squibb Company.
    • Bayer AG
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • Eli Lilly and Company
    • Pfizer Inc.
简介目录
Product Code: GVR-2-68038-513-7

Liver Cancer Drug Market Growth & Trends:

The global liver cancer drug market size is expected to reach USD 9.81 billion by 2030, registering a CAGR of 17.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75-90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

Liver Cancer Drug Market Report Highlights:

  • The targeted therapy segment held the largest market revenue share of 53.0% in 2023 due to its precision in targeting specific molecules or pathways involved in the growth and spread of cancer cells.
  • Hepatocellular Carcinoma (HCC) dominated the liver cancer drug market with a 36.6% revenue share in 2023. HCC Is the most common type of primary liver cancer.
  • Hospital pharmacy dominated the liver cancer drug market with a revenue share of 45.5% in 2023.
  • North America liver cancer drug market held a revenue share of 42.7% in 2023.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Liver Cancer Drug Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Liver Cancer Drug Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Liver Cancer Drug Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Liver Cancer Drug Market: Drug Movement Analysis, 2018 - 2030 (USD Million)
  • 4.3. Targeted Therapy
    • 4.3.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1. Bevacizumab
        • 4.3.1.1.1. Bevacizumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.2. Cabozantinib
        • 4.3.1.2.1. Cabozantinib Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.3. Lenvatinib
        • 4.3.1.3.1. Lenvatinib Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.4. Ramucirumab
        • 4.3.1.4.1. Ramucirumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.5. Regorafenib
        • 4.3.1.5.1. Regorafenib Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.6. Sorafenib
        • 4.3.1.6.1. Sorafenib Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.7. Other Targeted Therapies
        • 4.3.1.7.1. Other Targeted Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Immunotherapy
    • 4.4.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.1. Atezolizumab with Bevacizumab
        • 4.4.1.1.1. Atezolizumab with Bevacizumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.2. Nivolumab with Ipilimumab
        • 4.4.1.2.1. Nivolumab with Ipilimumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.3. Pembrolizumab
        • 4.4.1.3.1. Pembrolizumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.4. Durvalumab with Tremelimumab
        • 4.4.1.4.1. Durvalumab with Tremelimumab Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.4.1.5. Other Immunotherapies
        • 4.4.1.5.1. Other Immunotherapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Chemotherapy
    • 4.5.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.1. Gemcitabine
        • 4.5.1.1.1. Gemcitabine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.2. Oxaliplatin
        • 4.5.1.2.1. Oxaliplatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.3. Cisplatin
        • 4.5.1.3.1. Cisplatin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.4. Doxorubicin
        • 4.5.1.4.1. Doxorubicin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.5. 5-fluorouracil
        • 4.5.1.5.1. 5-fluorouracil Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.6. Capecitabine
        • 4.5.1.6.1. Capecitabine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.7. Mitoxantrone
        • 4.5.1.7.1. Mitoxantrone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.5.1.8. Other Chemotherapies
        • 4.5.1.8.1. Other Chemotherapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Liver Cancer Drug Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Liver Cancer Drug Market: Type Movement Analysis, 2018 & 2030 (USD Million)
  • 5.3. Hepatocellular Carcinoma
    • 5.3.1. Hepatocellular Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Cholangio Carcinoma
    • 5.4.1. Cholangio Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Hepatoblastoma
    • 5.5.1. Hepatoblastoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Liver Cancer Drug Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Liver Cancer Drug Market: Distribution Channel Movement Analysis, 2018 & 2030 (USD Million)
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacy
    • 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacy
    • 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Liver Cancer Drug Market: Regional Estimates & Trend Analysis

  • 7.1. Liver Cancer Drug Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK.
      • 7.3.2.1. UK Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Liver Cancer Drug Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Merck KGaA
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Exelixis, Inc.
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Eisai Co., Ltd.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Bristol-Myers Squibb Company.
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Bayer AG
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Novartis AG
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. F. Hoffmann-La Roche Ltd
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Eli Lilly and Company
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Pfizer Inc.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives